European markets close lower; Novo Nordisk down 20% after obesity drug results - CNBC
- European markets close lower; Novo Nordisk down 20% after obesity drug results CNBC
- Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps CNBC
- Ozempic maker’s shares plunge after failed weight-loss trial Yahoo! Voices
- Novo Nordisk Falls Most on Record After New Weight Drug Disappoints Bloomberg